23 — When the recipe changes

When the recipe changes.

+ The questionWhy does a supplier's or a maker's change reopen the evaluation?

A material passes through several owners

A foam can keep its name and its grade while the recipe inside it changes. Chapter 22 gave the reason such a change reopens the evaluation: its conclusion holds only for the materials and conditions it covered. The running device's sound-damping foam shows why the change can go unseen. Chemical suppliers make the polyol, the isocyanate, the catalysts and the surfactant (Chapter 3), and a foam maker reacts them into foam. The part is then cut and bonded into the machine (Chapter 6), and the user cleans the machine at home (Chapter 7). Each of these owners can change what the foam releases, and each knows only part of what the others did.

The supplier keeps the formulation to itself. What the device maker usually sees is a specification, a certificate that states what was tested on which material (Chapter 3), and a notice of change if their agreement asks for one. A device master file lets a supplier show its recipe to FDA without showing it to the customer, and FDA describes the file's purpose as helping to preserve the trade secrets of the industry that supplies device makers. The supplier files the information with FDA, which reviews it in confidence, and sends a letter of authorization "directly to a client", who cites the file in a 510(k) or another application. Once an approved application references the file, the authorization "cannot be withdrawn". FDA may also inspect the holder's facilities. The device maker thus gains a file that FDA has reviewed, but not the recipe in it.

56 — From the chemicals to the patient, and what each owner sees
CHEMICAL SUPPLIERS polyol · isocyanate · catalysts · surfactant (Ch 3) FOAM MAKER reacts them into foam; keeps the recipe DEVICE MAKER cuts, bonds and builds the part in (Ch 6) USER cleans the machine at home (Ch 7) the air the user breathes specification certificate: what was tested, on which material (Ch 3) notice of change, if the agreement asks for one instructions: cleaning agents, useful life (Ch 22) FDA master file: the recipe, reviewed in confidence letter of authorization, sent directly to the client what the foam releases changes if any owner changes the recipe or the process sees documents, not the recipe Schematic; this book's grouping of owners. Master file: FDA, Master Files web page, content current 6 December 2023.
Device materialReleased substanceGas or fluid pathFocal detail
Plate 56 — The foam passes through several owners before it reaches the user's air, and each can change what it releases. The device maker usually sees a specification, certificates and notices of change; through a master file, FDA can review the recipe that the device maker never sees.

Supplier controls are meant to catch a changed material

ISO 13485 is the quality-system standard that FDA's Quality Management System Regulation, the QMSR, incorporates (Chapter 26). The standard sets its purchasing controls in clause 7.4. As DQS, a certification body, described the clause in 2024, the controls "should be proportional to the associated risk", suppliers are evaluated and re-evaluated, and purchased product is checked by inspections and other activities. In the same account, clause 7.4.2 calls for "written agreements with supplier to ensure notification of change to the product" where the device maker judges them needed. Agarwal, a risk consultant writing the same year, presents such an agreement as best practice instead, so the two accounts leave open whether the clause itself requires one. The device maker carries the control, because the QMSR does not apply to the makers of components, as the preamble to FDA's final rule explains. The preamble has the maker do so through an ongoing assessment of each supplier, in which a certification alone may not be adequate.

FDA's Form 483 of November 2021 records a foam that passed through this control unseen. In its observation on purchasing controls, FDA wrote that the firm had "no established data, documentation, or written agreement that clearly describes or references the quality requirements of your raw foam supplier". The same observation records that an incorrect polyester polyurethane foam, not the one specified, came from that supplier into Trilogy Evo ventilators, and that the firm approved, released and distributed finished devices built with it. Related devices failed testing for volatile organic compounds under ISO 18562 (Chapter 20 gives the dates). Yet the firm's monitoring of that supplier, the form records, "documents no issues or concerns were observed".

Each part of the supplier control can catch only what it was set up to check. A certificate reports the supplier's tests against the supplier's own specification, so it cannot reveal a foam that differs from requirements the buyer never wrote down. A notice of change depends on an agreement that asks for one, and an incoming check finds only what it measures. For the running device, this book's design therefore writes down the buyer's requirements for the polyether foam, referencing the supplier's specification. It asks the supplier for notice before any change of formulation, raw material or production site, and it checks arriving lots against those requirements.

What counts as a change, and what it reopens

A change reopens the evaluation when it can alter what reaches the patient. FDA's 2017 guidance on changes to cleared devices tests for that with questions asked in order. The first is whether the change is one of "material type, material formulation, chemical composition, or the material's processing". The second is whether the changed material will "directly or indirectly contact body tissues or fluids". FDA counts a material that a gas passes through before it reaches the body as indirect contact, so the foam in the air path counts. The third is whether a risk assessment identifies "any new or increased biocompatibility concerns". The first question also takes in a new supplier: "if there is any change in supplier or manufacturer material processing or finishing steps, the answer should also be yes". The guidance has the maker analyze such a change through its quality system "even when these changes result in materials that remain within the original material specifications".

The changes that call for this review include a new grade or colorant, a new supplier or production site, a new process step, a different sterilization method and a changed cleaning instruction, which alters the conditions the evaluation assumed (Chapter 22). FDA's 2023 guidance on ISO 10993-1 names a change in resin supplier and changes in processing among those that can affect biocompatibility (Chapter 3), and it lists the sterilization process among the things to assess. A colorant added to the running device's cushion, this book's example, changes the silicone's formulation and touches skin, so it passes the first two questions. A maker may rely on the same material in a similar device, but the 2017 guidance draws that route narrowly: the material "should have the same formulation or chemical composition", and makers "should not compare their changed material to materials in other manufacturers' legally marketed devices". Without such a use, a new 510(k) "is likely required".

Every change is documented and reviewed, whether or not it needs a new submission. FDA's 2017 guidance notes that under the earlier Quality System Regulation, design and production changes needed review and approval "regardless of whether a change requires premarket review". ISO 13485 places the control of design changes in its clause 7.3.9. How far the review reaches is decided by the evaluation's own file. FDA's 2023 guidance asks whether a change affects the parts that contact tissue, and the trace of Chapter 22 links each part to its data. A colorant in the cushion therefore reopens the cushion's row, chemistry first, because earlier data stand in for tests only when formulation and processing match. The rows the change cannot reach keep their conclusions.

57 — A change through the questions, to the rows it reopens
PROPOSED CHANGE grade or colorant supplier or site process step sterilization method cleaning instruction A change of material type, formulation, chemical composition or processing? a change of supplier counts, even within the specification no Does the changed material contact the body, directly or indirectly? gas passing through a part counts as indirect contact no Does a risk assessment find a new or increased biocompatibility concern? the same material elsewhere counts only with the same formulation, never another maker's device; otherwise a new 510(k) is likely required no yes yes document the change and why the evaluation stands yes REOPEN THE ROWS IT CAN REACH gas pathway conclusion stands cushion chemistry first; tests only where it leaves a question (Ch 18) housing conclusion stands a colorant in the cushion: a formulation change on skin, so the cushion's row reopens Schematic. Questions: FDA, Deciding When to Submit a 510(k) for a Change to an Existing Device, 2017 (Flowchart C). Rows: this book's plan for the running device (Ch 22).
Device materialTissue and cellsGas or fluid pathFocal detail
Plate 57 — A proposed change passes FDA's questions in order, and a yes at each reopens only the rows of the evaluation that the change can reach. A colorant added to the running device's cushion changes its formulation and touches skin, so the cushion's row reopens from its chemistry.

The field reports what nobody announced

Some changes reach the evaluation only through the field, as complaints, returned devices and service reports that the loop of Chapter 22 brings back to the design. A trend among them can be the first sign that a material is no longer the one evaluated. Not every change starts at a supplier. FDA's Form 483 observed that the firm's "Procedures for design change have not been adequately established". Among the design changes not adequately verified, reviewed or validated before implementation, it counted changes to preventive maintenance schedules and servicing procedures (Chapter 20).

Packaging can change a device as a part can, and a recall outside breathing devices shows how. A knee insert's bag decides what the insert's polyethylene meets in storage (Chapter 7), so a bag without its barrier changes the device the patient receives. In one of FDA's records of a 2021 recall, Exactech's knee inserts were recalled because they "were packaged in vacuum bags that lacked an additional oxygen barrier layer", and FDA recorded the cause as process control. Products labeled with an 8-year shelf life and not packed in the barrier bags were to be removed in two phases over 12 months, and in February 2022 surgeons were told to "cease use of those devices".

Solved example: how often FDA's recall records name a change as the cause
  • The data. FDA's recall database, as it stood on 13 November 2026, assigns each record a root cause. Seven of its terms name a change control: process 965 records, labeling 604, component 532, packaging 304, vendor 288, software 218 and finished device 48.
  • The sum. 965 + 604 + 532 + 304 + 288 + 218 + 48 = 2,959 records. Device design alone has 7,676, so the change controls together come to about 4 records for every 10 of design.
  • The biological slice. Records whose reason contains the word "biocompatibility" number 104 across their causes. Device design has 76 of them, about 73 %, and process change control 2, about 2 %.
  • The result. Failed change controls fill thousands of records, but the database cannot show how often a change altered what a device releases, because a cause names the control that failed and a word search finds only reasons worded one way.
  • Assumptions. The counts are product records, not recall events, and they change daily; FDA calls the data unvalidated; a reason worded otherwise, such as a failed cytotoxicity test, is missed.

The replacement foam is a change too

A replacement material is itself a change, so it sends the evaluation around the loop again, starting from the plan. The firm replaced the recalled machines' polyester polyurethane foam with a silicone foam, whose test record Chapter 20 tells. For the evaluation, the new foam is a change of material type, the first kind that FDA's questions name, so the gas pathway's row reopens in full. The 2024 consent decree sets a testing plan for the new foam that follows the order of Chapter 22's plan, with ISO 18562 for the gas pathway first and ISO 10993 where that does not settle the risk (Chapter 26).

A different response is to leave the material out of the design. For another maker's PAP system, which FDA cleared in December 2025, the sponsor's summary states that "The PAP console of the subject device does not include foam." Leaving a material out removes its row from the evaluation. In this book's plan for the running device, a change to the polyether foam's supplier or formulation reopens the gas pathway's row. The new foam's emissions are then tested, new and aged, against the plan's acceptance criteria before the first machine with it ships.

In practice

Name each material's supplier, grade and production site in the purchasing file, and agree in writing with each supplier how a change of formulation, raw material, process or site will be notified. Treat a new colorant, supplier, process step, sterilization method or cleaning instruction as a change, and run it through the questions of FDA's change guidance and the evaluation's trace. Reopen the rows the change can reach, starting from chemistry, and record why the others stand. Watch complaints and service returns for a trend that points to a material that is no longer the one evaluated.

+ What this chapter established
  • A device's material passes through several owners. The device maker sees specifications, certificates and notices, while a master file lets FDA review a recipe the maker never sees.
  • Supplier control rests on the buyer's written requirements, an agreement to notify change and checks of what arrives. FDA's 2021 inspection recorded an incorrect foam, not the one specified, from a supplier whose quality requirements the firm had not set down in writing.
  • A change of material, formulation, supplier or processing reopens the evaluation wherever the changed part reaches the patient, directly or through the gas, even when the material still meets its specification.
  • A replacement material is itself a change, so the silicone foam that replaced the recalled polyester foam reopens the gas pathway's row in full.
Created with Claude (Anthropic).
Educational reference material, not engineering, regulatory or clinical advice. Product and company names referenced are the property of their respective owners.